Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Evozyne logo — Evozyne designs novel therapeutic proteins with generative A...

Evozyne

Evozyne designs novel therapeutic proteins with generative AI to solve immunology’s toughest challenges.

Founded 2020 United States Chicago, United States 55 employees Series B Total: $144.36M Biotechnology, Pharmaceutical

General Information

Company Name Evozyne
Founded Year 2020
Location United States Chicago, United States
Employees 55
Industries Biotechnology, Pharmaceutical
Funding Stage Series B
Business Model B2B, B2D
Revenue Model Licensing, Performance Based, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Evozyne. To contact Evozyne, visit evozyne.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Evozyne compare?

A PDF of Evozyne and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Evozyne soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Key Hire Oct 08, 2026

Radu Dobrin joins Evozyne as Chief Scientific Officer, leading AI-enabled protein design and drug discovery strategy.

Evozyne a competitor of yours? Have our desk watch it

About Evozyne

Evozyne, founded in 2020, is at the forefront of the Biotechnology and Pharmaceutical industries with its innovative approach to drug development. The company's slogan, "Generative AI-powered drug discovery platform and product development," encapsulates its mission to design novel protein therapeutics that meet previously unmet patient needs.

Headquartered in the United States, Evozyne employs cutting-edge technologies to revolutionize the way protein therapeutics are discovered and developed. This approach not only accelerates the drug discovery process but also enhances the potential for tackling complex, untreated health challenges.

In its recent Series B investment, Evozyne secured a substantial $81.00M in funding on 01 September 2023 from top investors, including Valor Equity Partners, OrbiMed, Paragon Biosciences, nVentures, and Fidelity Investments. This infusion of capital is expected to propel the company's growth and expand its capabilities in developing groundbreaking therapeutics that address critical patient needs.

Business keywords: Generative AI, Drug Discovery, Protein Design, Therapeutic Discovery, Molecular Scale, Novel Protein Therapeutics, Healthcare Innovation, AI in Drug Development, Complex Challenges, Protein Engineering, Societal Challenges Solution

Services & Products

AI-native Protein Design
Protein Synthesis and Testing
Therapeutic Protein Development
Immunology Pipeline Advancement

Target Customers

Patients with High Unmet Need in Immune-Mediated Diseases Healthcare Providers Pharmaceutical Companies

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $81.00M 5
Valor Equity Partners OrbiMed Paragon Biosciences
Valor Equity Partners, OrbiMed +3
01 Sep 2023
Series A $54.18M -
01 Apr 2021
Early VC $9.18M -
01 Apr 2020
Spinout Undisclosed 1
The University of Chicago
The University of Chicago
01 Jan 2020

Evozyne Alternatives & Competitors

View All Alternatives
Evozyne vs
AQEMIA
AQEMIA France

Scale drug discovery with quantum-inspired physics and generative AI

87 employees
AI, Biotechnology
Compare Evozyne vs AQEMIA
Evozyne vs
Generate:Biomedicines
Generate:Biomedicines United States

Pioneering generative biology to create breakthrough therapeutics.

IPO
335 employees
Biotechnology, Pharmaceutical
Compare Evozyne vs Generate:Biomedicines
Evozyne vs
ProFound Therapeutics
ProFound Therapeutics

Pioneering the expanded human proteome to reveal a universe of new medicines.

51 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About Evozyne

Evozyne designs novel therapeutic proteins with generative AI to solve immunology’s toughest challenges.
Evozyne was founded in 2020.
Evozyne is headquartered in Chicago, United States.
Evozyne operates in Biotechnology and Pharmaceutical. Its work centres on Generative AI, Drug Discovery, Protein Design and Therapeutic Discovery. Its customers include Patients with High Unmet Need in Immune-Mediated Diseases, Healthcare Providers and Pharmaceutical Companies.
Evozyne has a B2B and B2D business model. Its revenue comes from Licensing, Performance Based and Service Fee.
Evozyne has approximately 55 employees.
Evozyne has completed 4 funding rounds, raising a total of $144.36M. The latest funding stage is Series B.
Evozyne offers: AI-native Protein Design, Protein Synthesis and Testing, Therapeutic Protein Development, Immunology Pipeline Advancement.
Top alternatives and competitors to Evozyne include AQEMIA, Generate:Biomedicines, ProFound Therapeutics, Differentiated Therapeutics Inc, KSQ Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Evozyne and AQEMIA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Evozyne, https://bouncewatch.com/company/evozyne, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout